Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer - NeoCOAST-2

Study identifier:D9077C00001

ClinicalTrials.gov identifier:NCT05061550

EudraCT identifier:2021-003369-37

CTIS identifier:N/A

Recruiting

Official Title

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig

Sex

All

Estimated Enrollment

490

Study type

Interventional

Age

18 Years - 95 Years

Date

Study Start Date: 14 Apr 2022
Estimated Primary Completion Date: 09 May 2030
Estimated Study Completion Date: 09 May 2030

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Parexel International

Inclusion and exclusion criteria